裕興科技(08005.HK)擴大對綜合醫療保健及生物製藥行業投資
格隆匯12月1日丨裕興科技(08005.HK)公吿，於2021年12月1日，公司直接全資附屬公司利富與目標公司Profound View Group就利富認購目標公司普通股股份訂立認購協議。認購事項的代價將為4800萬港元。
完成後，利富將持有目標公司經擴大後股本合共8.41%。目標集團財務業績將不會併入集團綜合財務報表。
集團致力開拓新商機，並有意拓寬其現有投資組合，以及集團未來發展具有良好的資產。集團目前的投資組合包括上市證券、基金、數字資產及從事飛機租賃及融資的公司。認購事項為集團提供了擴大其對綜合醫療保健及生物製藥行業的投資，並提升股東價值的機會。
目標集團於中國主要從事1.1類神經退行性疾病創新化學藥物的醫藥創新藥物及生物製劑研發，尤其針對阿茲海默病、帕金森症及青光眼的病症。隨着創新生物藥的價值逐步提升，中國生物製藥企業的創新生物藥種類在不斷改變，已從me-too類型的新藥(指與現有藥物相似的藥物，通常是對原型進行細微修改)轉向具有高價值及迫切臨牀需求的通用創新藥(best-in-class)和創新藥(first-in-class)，轉向具有高價值及迫切臨牀需求的通用創新藥(best-in-class)和創新藥(first-inclass)，這表明對創新藥物的需求不斷上升。
自2015年8月18日《國務院關於改革藥品醫療器械審評審批制度的意見》頒佈後，中國獲批的創新藥數量一直在增長。於2020年受到冠狀病毒病(COVID-19)疫情的影響，導致創新藥獲批數量下降，但也是首次中國與跨國創新藥的批准數量接近。
為把握勢頭，集團希望把握投資機遇，開發具有商業化潛力及潛在利潤豐厚市場的非治癒性疾病的新藥開發。監於(i)生物製藥行業有一個新興的創新藥市場，受到政府優惠政策的支持；及(ii)目標集團於國內外生物製藥領域對神經退行性疾病的醫學研發貢獻方面的前景，董事會(包括獨立非執行董事)認為，訂立認購協議將有助於集團未來將獲得良好的投資回報。
董事會(包括獨立非執行董事)確認，認購協議及其項下擬進行的交易的條款為：(i)公平合理，按正常商業條款或更佳條款，並在正常及日常業務過程中團體；及(ii)符合公司及其股東的整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
